Perrigo's Europe-focused consumer health business Omega Pharma found sales growth hard to come by in 2018 as the group worked hard to right size the organization. While it still has a way to go to completely turnaround Omega, Perrigo is starting to see these interventions pay off, with profits up for the 12 months.
Continued efforts by Perrigo Co. PLC to restructure and right-size its Omega Pharma NV consumer health operation hit sales at the Europe-focused business in 2018, with turnover down by 5% for the 12 months.
Perrigo blamed the single-digit slide in Omega’s sales to €988m on the termination of “unprofitable” distribution contracts in Belgium and...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
